Clinicians may one day be able to treat immune checkpoint inhibitor-related myocarditis without disrupting cancer therapy, findings from a cellular investigation showed.Individuals who die of immune ...

The generic drugmaker was the top loser on the Nifty Pharma index and the benchmark Nifty 50 index. "The drop in shares comes ...

As many American companies beat a hasty retreat from the diversity, equity and inclusion programs they once embraced, the bulk retailer Costco Wholesale Corp. has become one of DEI’s few remaining ...

This was the stock's third consecutive day of gains.

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...

The two biggest questions for SCHD right now are 1) what’s caused it to underperform so badly, even within its category and 2) will those trends continue into 2025.

Kura Oncology's stock plummeted 50% after announcing a collaboration with Kyowa Kirin, making it a less attractive ...

The American College of Cardiology announced the late-breaking science lineup for its Scientific Session to be held March ...

Chip makers like Nvidia are far from the only beneficiaries of President Trump’s effort to make the U.S. a leader in ...

We recently published a list of Jim Cramer Discusses TikTok Ban, President Trump & These 6 Stocks. In this article, we are ...

CARE Pharmacies appointed Ryan Hollingsworth, Natalie Ryan and Steven Pieri to its 2025 board of directors, and Lionel Phillips will serve as vice chairman on its executive committee.

From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024.